Fatty liver disease (MASLD) in Black patients: what the data actually shows

MASLD stands for metabolic dysfunction-associated steatotic liver disease. In June 2023, three major liver societies (the American, European, and Latin American associations) retired the old name, NAFLD (nonalcoholic fatty liver disease), and replaced it with MASLD. The change followed a consensus process with 236 experts from 56 countries. The goal was to name the disease for what drives it, metabolic dysfunction, instead of for what it is not (alcohol).

The diagnosis requires two things: fat in the liver plus at least one cardiometabolic risk factor, such as elevated weight or waist size, high blood sugar or diabetes, high blood pressure, high triglycerides, or low HDL cholesterol.

There is a spectrum. Plain fatty liver is fat without much inflammation. The more serious form, now called MASH (formerly NASH), adds inflammation and liver cell damage. MASH is what causes fibrosis, the scarring that, over years, can progress to cirrhosis and liver failure.

Here is the part that surprises people. You would expect a community with high rates of obesity, type 2 diabetes, and metabolic syndrome to have the most fatty liver disease. The data says the opposite.

A 2018 systematic review and meta-analysis in Clinical Gastroenterology and Hepatology pooled 34 studies covering 368,569 people. It found NAFLD prevalence was highest in Hispanic Americans, intermediate in white Americans, and lowest in Black Americans. In population-based cohorts the figures were roughly 23 percent (Hispanic), 14 percent (white), and 13 percent (Black).

The pattern holds even after accounting for risk factors. In several analyses, the link between type 2 diabetes or obesity and fatty liver was weaker in Black patients than in white patients. The same meta-analysis found that among people who already have the disease, the risk of progressing to MASH was lower in Black Americans (relative risk 0.72 versus white Americans) and somewhat higher in Hispanic Americans.

This is genuine. It is also frequently misread, so three cautions:

First, lower prevalence is not protection. Black Americans still have high baseline rates of the metabolic conditions that cause MASLD, and plenty of Black patients have it. A population average says nothing about any one person.

Second, the gap is smaller than the headline suggests in high-risk groups. The same review found that in cohorts already enriched for disease, prevalence across groups clustered much closer together (roughly 48 percent to 56 percent). The disparity is widest in the general population, narrower among the sick.

Third, measurement and access matter. Disparities in who gets tested, referred, and biopsied can distort prevalence numbers, and some of the apparent gap reflects unequal care rather than biology alone.

The strongest explanation is genetic. A landmark 2008 study in Nature Genetics, using the multiethnic Dallas Heart Study, identified a variant in the PNPLA3 gene (rs738409, also called I148M) that strongly raises liver fat. The fat-promoting variant was carried by about 49 percent of Hispanic Americans, 23 percent of European Americans, and only 17 percent of African Americans, mirroring the prevalence pattern almost exactly. The researchers also found a separate PNPLA3 allele associated with lower liver fat that was more common in African Americans.

Genetics is not the whole story. Diet, body fat distribution, and social determinants of health all play roles. But PNPLA3 is the single clearest reason the prevalence map looks the way it does.

Most people with MASLD feel nothing. The liver does not register early fat buildup or even early scarring with pain or obvious symptoms. According to the NIDDK, fatty liver disease is usually a silent disease with few or no symptoms, and you may have no symptoms even after cirrhosis has developed.

That is the danger. By the time fatigue, abdominal discomfort, or signs of advanced liver disease appear, scarring may already be significant. Silent does not mean harmless. It means the only reliable way to find it is to look.

Because symptoms are unreliable, screening targets people with risk factors: type 2 diabetes, obesity, and metabolic syndrome. The workup is mostly non-invasive.

• Blood tests. Elevated liver enzymes (ALT and AST) can flag the disease, though enzymes are often normal even when fat is present.
• FIB-4 score. A simple calculation using age, those liver enzymes, and platelet count estimates the chance of advanced scarring. Under the 2023 AASLD guidance, FIB-4 below 1.3 is low risk, above 2.67 is high risk, and in between is indeterminate.
• FibroScan (vibration-controlled transient elastography). A painless ultrasound-based scan that measures liver stiffness, used as the next step when FIB-4 is indeterminate or high.
• Imaging and, rarely, biopsy. Ultrasound or specialized MRI can quantify fat. Liver biopsy remains the most definitive way to distinguish plain fatty liver from MASH, but it is reserved for cases where the answer changes treatment.

If you have diabetes or obesity, ask your clinician whether a FIB-4 score and, if needed, a FibroScan make sense for you. A primary care clinician or hepatologist can order these.

The good news is that the treatments work the same regardless of race, and the foundation is metabolic.

• Weight loss. The AASLD guidance targets 7 to 10 percent body-weight loss for people with excess weight. That degree of loss can reduce liver fat and inflammation, and larger losses can improve fibrosis. A Mediterranean-style diet is the standard recommendation.
• Controlling diabetes. Because type 2 diabetes is a primary driver, tight glucose control is central to protecting the liver.
• GLP-1 medications. In August 2025, the FDA approved semaglutide (Wegovy) for adults with MASH and moderate-to-advanced fibrosis. In its trial, about 63 percent of people on semaglutide had their steatohepatitis resolve without worsening scarring, versus 34 percent on placebo. It is not approved for people who already have cirrhosis, and it works alongside diet and exercise, not instead of them. If you are weighing this route, see our guide to GLP-1 medications.
• Resmetirom (Rezdiffra). In March 2024 it became the first drug ever approved specifically for MASH with moderate-to-advanced fibrosis, used together with diet and exercise.

It says: in U.S. populations, fatty liver disease is measurably less common in Black Americans than in white or Hispanic Americans, and progression to MASH appears somewhat less likely, with a clear genetic basis in PNPLA3.

It does not say: that Black people cannot get MASLD, that screening is less important, or that the disease is mild when it does occur. Lower average prevalence is a population statistic, not a personal shield. The risk factors that cause it, obesity and diabetes, remain common, the disease stays silent until late, and an individual with those risk factors deserves screening regardless of what the population average shows.